NRX Pharmaceuticals Warrant
NRXPW
NRXPW was delisted on the 22nd of May, 2026.
5 hedge funds and large institutions have $486K invested in NRX Pharmaceuticals Warrant in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
25% more funds holding
Funds holding: 4 → 5 (+1)
15% less capital invested
Capital invested by funds: $573K → $486K (-$87K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$105K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$14.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$282K |
| 2 |
ICM
Ionic Capital Management
New York
|
-$72K |
| 3 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$71.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AA
1
AQR Arbitrage
Greenwich,
Connecticut
| $255K | -$282K | -45,744 | -46% |
|
|
YCM
2
Yakira Capital Management
Westport,
Connecticut
| $139K | -$71.9K | -11,652 | -29% |
|
|
3
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $81K | +$105K | +16,970 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $11K | +$14.6K | +2,373 | New |
|
|
ICM
5
Ionic Capital Management
New York
| – | -$72K | -20,117 | Closed |
|
NRXPW Hedge Fund Activity: Q3 2021 in Review
5 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q3 2021, worth a combined $486K — down 15% from $573K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NRXPW positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $105K. The largest seller was AQR Arbitrage, cutting an estimated $282K.
- 5 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q3 2021, up from 4 in Q2 2021.
- Funds reported $486K of NRX Pharmaceuticals Warrant stock for Q3 2021, down 15% quarter-over-quarter.
- 2 funds opened new NRX Pharmaceuticals Warrant positions in Q3 2021 and 1 closed out, a net change of +1 holder.
- The largest NRX Pharmaceuticals Warrant buyer in Q3 2021 was Cambridge Investment Research Advisors, an estimated $105K added.
- The largest NRX Pharmaceuticals Warrant seller in Q3 2021 was AQR Arbitrage, an estimated $282K sold.
Based on aggregated 13F filings for Q3 2021.